Applied Therapeutics
APLT
APLT was delisted on the 2nd of February, 2026.
40 hedge funds and large institutions have $40.3M invested in Applied Therapeutics in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 3 closing their positions.
161,033% more call options, than puts
Call options by funds: $9.67M | Put options by funds: $6K
158% more capital invested
Capital invested by funds: $15.6M → $40.3M (+$24.6M)
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
14.32% more ownership
Funds ownership: 40.07% → 54.39% (+14%)
11% more funds holding
Funds holding: 36 → 40 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$7.51M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4.82M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$4.21M |
| 4 |
CM
CM Management
Gulf Breeze,
Florida
|
+$398K |
| 5 |
Renaissance Technologies
New York
|
+$249K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$442K |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$325K |
| 3 |
Citigroup
New York
|
-$286K |
| 4 |
Millennium Management
New York
|
-$178K |
| 5 |
Two Sigma Investments
New York
|
-$85.7K |
APLT Hedge Fund Activity: Q2 2023 in Review
40 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Applied Therapeutics (APLT) for Q2 2023, worth a combined $40.3M — up 158% from $15.6M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new APLT positions and 3 closed out — a net gain of 4 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $7.51M. The largest seller was Fidelity Investments, cutting an estimated $442K.
- 40 institutional investors held Applied Therapeutics (APLT) as of Q2 2023, up from 36 in Q1 2023.
- Funds reported $40.3M of Applied Therapeutics stock for Q2 2023, up 158% quarter-over-quarter.
- 7 funds opened new Applied Therapeutics positions in Q2 2023 and 3 closed out, a net change of +4 holders.
- The largest Applied Therapeutics buyer in Q2 2023 was VR Adviser, an estimated $7.51M added.
- The largest Applied Therapeutics seller in Q2 2023 was Fidelity Investments, an estimated $442K sold.
Based on aggregated 13F filings for Q2 2023.